NCT06703892View on ClinicalTrials.gov

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

December 31, 2027

Conditions
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma RefractoryFollicular Lymphoma ( FL)Primary Mediastinal Large B-Cell Lymphoma-RefractoryPrimary Mediastinal Large B-Cell Lymphoma-RecurrentHigh-grade B-cell Lymphoma (HGBCL)
Interventions
BIOLOGICAL

GF-CART01

CAR positive viable T cells-Mid

BIOLOGICAL

GF-CART01

CAR positive viable T cells-High

BIOLOGICAL

GF-CART01

CAR positive viable T cells-Low

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

GenomeFrontier Therapeutics TW Co., Ltd.

INDUSTRY

NCT06703892 - A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies | Biotech Hunter | Biotech Hunter